ACRV Stock Summary and Trading Ideas (Acrivon Therapeutics | NASDAQ:ACRV)

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Acrivon Therapeutics trades on the NASDAQ stock market under the symbol ACRV.

As of January 9, 2026, ACRV stock price declined to $1.75 with 3,667,576 million shares trading.

ACRV has a beta of 2.01, meaning it tends to be more sensitive to market movements. ACRV has a correlation of 0.09 to the broad based SPY ETF.

ACRV has a market cap of $55.22 million. This is considered a Micro Cap stock.

In the last 3 years, ACRV traded as high as $25.47 and as low as $1.05.

The top ETF exchange traded funds that ACRV belongs to (by Net Assets): VTI, VXF, IWC.

ACRV has underperformed the market in the last year with a price return of -71.3% while the SPY ETF gained +19.0%. ACRV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -10.7% and -28.3%, respectively, while the SPY returned +3.7% and +0.5%, respectively.

ACRV support price is $1.78 and resistance is $2.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRV shares will trade within this expected range on the day.